AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34480008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; maltodextrin) with HI warm-up
Number of subjects: 12
Study 34480008 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; maltodextrin) with LI warm-up
Number of subjects: 12
Study 36147018 — intervention group
Group type: EXPERIMENTAL
Intervention: CBMT + TAU (Cognitive Bias Modification Training + Treatment as Usual)
Number of subjects: 67
Study 36147018 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 67
Study 33023750 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus feeding regimen
Number of subjects: 0
Study 33023750 — intervention group
Group type: COMPARATOR
Intervention: Continuous feeding regimen
Number of subjects: 0
Study 34819195 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models (elastic net regressions and random forests)
Number of subjects: 191
Study 34819195 — intervention group
Group type: COMPARATOR
Intervention: Traditional models (logistic/linear regressions)
Number of subjects: 191
Study 34212998 — intervention group
Group type: EXPERIMENTAL
Intervention: C Mac D‐Blade videolaryngoscope
Number of subjects: 56
Study 34212998 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 56
Study 35191430 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Papillary Large Balloon Dilation (EPLBD)
Number of subjects: 180
Study 33688836 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised invitation strategy with prenotification postcard (Group 2)
Number of subjects: 4633
Study 33688836 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised invitation strategy with prenotification postcard (Group 3)
Number of subjects: 4633
Study 33688836 — intervention group
Group type: EXPERIMENTAL
Intervention: New invitation without prenotification postcard (Group 4)
Number of subjects: 4633
Study 33688836 — intervention group
Group type: COMPARATOR
Intervention: Original invitation (Control Group 1)
Number of subjects: 4633
Study 33688836 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participation rate
Number of subjects: 4633
Study 33688836 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensibility of invitations
Number of subjects: 4633
Study 33110020 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabiximol (cannabis extract)
Number of subjects: 0
Study 35212286 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium longum NT strain 1010 CFU/day)
Number of subjects: 69
Study 35212286 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (Bifidobacterium longum NT strain 1010 CFU/day and galactooligosaccharide 1 g/day)
Number of subjects: 69
Study 35212286 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo foods containing vehicle only)
Number of subjects: 69
Study 32561467 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET) addressing PTSD
Number of subjects: 0
Study 32561467 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing with cognitive behavioral therapy skills training (MIST) addressing substance misuse
Number of subjects: 0
Study 35724489 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application of diabetes coaching intervention (12 weeks)
Number of subjects: 0
Study 35724489 — intervention group
Group type: COMPARATOR
Intervention: Usual care from community health centers
Number of subjects: 0
Study 32556709 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-Biofeedback (HRV-Bfb)
Number of subjects: 69
Study 32556709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions (MBI)
Number of subjects: 69
Study 32556709 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (WLC)
Number of subjects: 69
Study 34330458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursolic acid (UA) supplementation (450 mg/day)
Number of subjects: 26
Study 34330458 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 26
Study 33048901 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsedation with sufficient analgesia
Number of subjects: 205
Study 33048901 — intervention group
Group type: COMPARATOR
Intervention: Light sedation with a daily wake‐up call
Number of subjects: 205
Study 35779065 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS levels
Number of subjects: 34
Study 33813345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dove Confident Me intervention (five sessions facilitated by trained psychologists)
Number of subjects: 166
Study 33813345 — intervention group
Group type: COMPARATOR
Intervention: Lessons-as-usual (control)
Number of subjects: 166
Study 36163254 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP; 60 mg)
Number of subjects: 0
Study 36163254 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study 33413144 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional resistance and balance training (3 d/wk)
Number of subjects: 116
Study 33413144 — intervention group
Group type: COMPARATOR
Intervention: Usual care phase‐II‐CR inpatient multidisciplinary CR program
Number of subjects: 116
Study 32087001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate single-dose (5 to 750 mg)
Number of subjects: 210
Study 32087001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate multiple-dose (50 to 600 mg/day)
Number of subjects: 210
Study 32087001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 32087001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (all doses)
Number of subjects: 210
Study 32087001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (multiple daily doses of 600 mg)
Number of subjects: 210
Study 36017875 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab consolidation therapy
Number of subjects: 48
Study 36017875 — intervention group
Group type: COMPARATOR
Intervention: No consolidation
Number of subjects: 48
Study 36017875 — intervention group
Group type: COMPARATOR
Intervention: Monitoring group (MRD-negative patients)
Number of subjects: 48
Study 33587687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZIKV.001 (5 × 10^10 vp)
Number of subjects: 100
Study 33587687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZIKV.001 (1 × 10^11 vp)
Number of subjects: 100
Study 33587687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZIKV.001 (1 × 10^11 vp, 1-dose regimen)
Number of subjects: 100
Study 33587687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 34973081 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine/antidepressant
Number of subjects: 702
Study 34973081 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine
Number of subjects: 702
Study 34523035 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen cannula (HFNC)
Number of subjects: 222
Study 34523035 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive mechanical ventilation (NIV)
Number of subjects: 222
Study 32589319 — intervention group
Group type: EXPERIMENTAL
Intervention: My Baby's First Teacher intervention
Number of subjects: 45
Study 32589319 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (control)
Number of subjects: 45
Study 36084200 — intervention group
Group type: EXPERIMENTAL
Intervention: iTAB+MI
Number of subjects: 255
Study 33373701 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1g intravenous infusion)
Number of subjects: 203
Study 33373701 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (40mg intravenous infusion)
Number of subjects: 203
Study 34951331 — intervention group
Group type: EXPERIMENTAL
Intervention: PTES-K (Korean Version of the Perceived Therapeutic Efficacy Scale)
Number of subjects: 108
Study 34951331 — intervention group
Group type: EXPERIMENTAL
Intervention: PTES-K
Number of subjects: 108
Study 32787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management behaviors (medication therapy, diet therapy, exercise, tobacco and alcohol avoidance, stress reduction, self-monitoring/self-care)
Number of subjects: 148
Study 32787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management behaviors (diet therapy)
Number of subjects: 148
Study 32787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management behaviors (self-monitoring/self-care)
Number of subjects: 148
Study 32787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management behaviors (exercise)
Number of subjects: 148
Study 32787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management behaviors (tobacco and alcohol avoidance)
Number of subjects: 148
Study 32787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management behaviors (medication therapy)
Number of subjects: 148
Study 32787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy as a mediator
Number of subjects: 148
Study 36028977 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media use (Instagram®) for 30 minutes before training
Number of subjects: 18
Study 36028977 — intervention group
Group type: COMPARATOR
Intervention: Watching TV for 30 minutes before training (Control)
Number of subjects: 18
Study 33538782 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy (MRI-TB)
Number of subjects: 453
Study 33538782 — intervention group
Group type: COMPARATOR
Intervention: Systematic 12-core TRUS biopsy
Number of subjects: 453
Study 35486131 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid in combination with ezetimibe
Number of subjects: 0
Study 35486131 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid in addition to statins
Number of subjects: 0
Study 35486131 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 0
Study 34850039 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (RZV)
Number of subjects: 160
Study 35277986 — intervention group
Group type: EXPERIMENTAL
Intervention: clinician + self‐determined monitoring
Number of subjects: 48
Study 35277986 — intervention group
Group type: COMPARATOR
Intervention: clinician‐determined monitoring
Number of subjects: 48
Study 35623877 — intervention group
Group type: EXPERIMENTAL
Intervention: Morus Alba extract (300 mg)
Number of subjects: 60
Study 35623877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33314776 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Transforaminal Endoscopic Discectomy (PTED)
Number of subjects: 136
Study 33314776 — intervention group
Group type: COMPARATOR
Intervention: Open Fenestration Discectomy (OFD)
Number of subjects: 136
Study 33314776 — intervention group
Group type: COMPARATOR
Intervention: Both PTED and OFD
Number of subjects: 136
Study 35142231 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing for 15 minutes
Number of subjects: 15
Study 32144511 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial photobiomodulation using 945-nm LEDs for 1 min and 25 s (9.35 J/cm2)
Number of subjects: 22
Study 32144511 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (device off)
Number of subjects: 22
Study 35758257 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefing
Number of subjects: 45
Study 35758257 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback
Number of subjects: 45
Study 35304155 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2g to 4g per day
Number of subjects: 98
Study 35304155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 35179454 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to improve skin and needle hygiene
Number of subjects: 252
Study 34380636 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 positive (IHC 3+)
Number of subjects: 755
Study 34380636 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 positive DCIS
Number of subjects: 755
Study 34380636 — intervention group
Group type: COMPARATOR
Intervention: HER2 negative DCIS
Number of subjects: 755
Study 32579195 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine with standard medical treatment
Number of subjects: 105
Study 32579195 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 105
Study 36065050 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS‐AHM
Number of subjects: 712
Study 33471547 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive active exercise therapy (PR)
Number of subjects: 82
Study 33471547 — intervention group
Group type: COMPARATOR
Intervention: Limited passive exercise therapy (UC)
Number of subjects: 82
Study 33471547 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PR and UC)
Number of subjects: 82
Study 32540337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab consolidation (500 mg/m2 biweekly × 6)
Number of subjects: 63
Study 32540337 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 63
Study 32966574 — intervention group
Group type: EXPERIMENTAL
Intervention: RBX7455 (4 capsules twice daily for 4 days)
Number of subjects: 30
Study 32966574 — intervention group
Group type: EXPERIMENTAL
Intervention: RBX7455 (4 capsules twice daily for 2 days)
Number of subjects: 30
Study 32966574 — intervention group
Group type: EXPERIMENTAL
Intervention: RBX7455 (2 capsules twice daily for 2 days)
Number of subjects: 30
Study 32966574 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 32966574 — intervention group
Group type: EXPERIMENTAL
Intervention: RBX7455
Number of subjects: 30
Study 33513054 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct brain cooling at 32°C
Number of subjects: 14
Study 33513054 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study 35107188 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine in combination with standard care
Number of subjects: 202
Study 35107188 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 202
Study 33400027 — intervention group
Group type: EXPERIMENTAL
Intervention: reTAPP (repeated transabdominal preperitoneal laparoscopic repair)
Number of subjects: 46
Study 33400027 — intervention group
Group type: COMPARATOR
Intervention: Conventional open repair (Lichtenstein technique)
Number of subjects: 46
Study 35964114 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Health Activity Motor Program-Afterschool Program (CHAMP-ASP)
Number of subjects: 264
Study 35964114 — intervention group
Group type: COMPARATOR
Intervention: Comparison Afterschool Program (ASP)
Number of subjects: 264
Study 34480720 — intervention group
Group type: EXPERIMENTAL
Intervention: Needlescopic surgery (NEED)
Number of subjects: 30
Study 34480720 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy (LAP)
Number of subjects: 30
Study 33023357 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 2401
Study 33023357 — intervention group
Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 2401
Study 33023357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2401
Study 34062263 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenols as adjunctive treatments
Number of subjects: 0
Study 34062263 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenols
Number of subjects: 0
Study 32769849 — intervention group
Group type: EXPERIMENTAL
Intervention: CMX-2043 (2.4 mg/kg)
Number of subjects: 142
Study 32769849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 36197656 — intervention group
Group type: COMPARATOR
Intervention: Completely successful belief about antibiotics
Number of subjects: 776
Study 36197656 — intervention group
Group type: COMPARATOR
Intervention: Intermediate belief about antibiotics
Number of subjects: 776
Study 33517830 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of influenza vaccine availability
Number of subjects: 1377
Study 33517830 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of free influenza vaccine availability
Number of subjects: 1377
Study 33517830 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in vaccine efficacy
Number of subjects: 1377
Study 33517830 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in vaccine safety
Number of subjects: 1377
Study 32835919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fennel seed extract (200 mg per capsule, 4 capsules daily for 2 weeks)
Number of subjects: 66
Study 32835919 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 capsules daily for 2 weeks)
Number of subjects: 66
Study 32835919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fennel seed extract
Number of subjects: 66
Study 32835919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 35296528 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led patient education intervention (face-to-face education by a nurse at baseline and 3 months later)
Number of subjects: 129
Study 35296528 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 129
Study 35296528 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led patient education intervention
Number of subjects: 129
Study 32574006 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP group
Number of subjects: 302
Study 32574006 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 302
Study 34668963 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy (n=528)
Number of subjects: 1056
Study 34668963 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (n=528)
Number of subjects: 1056
Study 34668963 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy
Number of subjects: 1056
Study 34668963 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy
Number of subjects: 1056
Study 34110580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer lactate solution (RLS)
Number of subjects: 42
Study 34110580 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (NSS)
Number of subjects: 42
Study 34110580 — intervention group
Group type: COMPARATOR
Intervention: Sterofundin
Number of subjects: 42
Study 616788753 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training for 8 weeks, 3 sessions per week at 50-70% of 1RM
Number of subjects: 30
Study 616788753 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 33420104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendiocarb exposure during pregnancy
Number of subjects: 0
Study 32876695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg IV daily for 5 days or 10 mg IV daily for 5 days until ICU discharge) plus standard care
Number of subjects: 299
Study 32876695 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 299
Study 36346783 — intervention group
Group type: EXPERIMENTAL
Intervention: PediQUEST Response
Number of subjects: 200
Study 36346783 — intervention group
Group type: COMPARATOR
Intervention: Usual Cancer Care
Number of subjects: 200
Study 34236794 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-thermal plasma kinetic cautery (PKC)
Number of subjects: 258
Study 34236794 — intervention group
Group type: COMPARATOR
Intervention: Conventional monopolar electrosurgery (CMES)
Number of subjects: 258
Study 33160571 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloons (DCB)
Number of subjects: 0
Study 33160571 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 33168504 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable circumcision suture device (DCSD)
Number of subjects: 236
Study 33168504 — intervention group
Group type: COMPARATOR
Intervention: Conventional circumcision (CC)
Number of subjects: 236
Study 34556856 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (320 mg daily in adults; 80-160 mg daily in children)
Number of subjects: 178
Study 35345654 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined intravenous anesthesia
Number of subjects: 285
Study 35345654 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous anesthesia
Number of subjects: 285
Study 32161953 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of ketone bodies during a hyperinsulinemic-euglycemic clamp
Number of subjects: 8
Study 32161953 — intervention group
Group type: COMPARATOR
Intervention: Infusion of saline during a hyperinsulinemic-euglycemic clamp
Number of subjects: 8
Study 34089846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lirentelimab (AK002), an antibody against siglec-8 that depletes eosinophils and inhibits mast cells.
Number of subjects: 88
Study 34089846 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple biopsies (8 gastric and 4 duodenal)
Number of subjects: 88
Study 37497068 — intervention group
Group type: EXPERIMENTAL
Intervention: MEntA Program based on motivational interview for adherence
Number of subjects: 0
Study 37497068 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 35230440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical chemotherapy after TURBT
Number of subjects: 0
Study 32028974 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg intravenously on day 1 and gemcitabine 1000 mg/m2 intravenously on days 1 and 8 every 21 days until disease progression or unacceptable toxicity
Number of subjects: 19
Study 32028974 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab and gemcitabine combination therapy
Number of subjects: 19
Study 34839204 — intervention group
Group type: COMPARATOR
Intervention: Five-degree lateral wedge insole (LWI)
Number of subjects: 17
Study 34839204 — intervention group
Group type: COMPARATOR
Intervention: Off-the-shelf knee sleeve
Number of subjects: 17
Study 34839204 — intervention group
Group type: COMPARATOR
Intervention: Knee sleeve
Number of subjects: 17
Study 34839204 — intervention group
Group type: COMPARATOR
Intervention: Combined LWI and knee sleeve
Number of subjects: 17
Study 34839204 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 17
Study 33827091 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 L/min bias gas flow
Number of subjects: 95
Study 33827091 — intervention group
Group type: COMPARATOR
Intervention: 10 L/min bias gas flow
Number of subjects: 95